Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure

医学 脂肪组织 心力衰竭 心脏病学 肥胖 内科学 脂肪团
作者
Christopher M. Kramer,Barry A. Borlaug,Michael R. Zile,Dustin Ruff,Joseph M DiMaria,Venu Menon,Yang Ou,Angela M Zarante,Karla Hurt,Masahiro Murakami,Milton Packer
出处
期刊:Journal of the American College of Cardiology [Elsevier BV]
卷期号:85 (7): 699-706 被引量:156
标识
DOI:10.1016/j.jacc.2024.11.001
摘要

BACKGROUND: Obesity is a known risk factor for heart failure with preserved ejection fraction (HFpEF) and is considered a distinct phenotype with more concentric remodeling. Epicardial adipose tissue (EAT) is also increased in obesity-related HFpEF and is associated with adverse events. OBJECTIVES: The cardiac magnetic resonance (CMR) substudy of the SUMMIT trial aimed to examine the effects of tirzepatide on cardiac structure and function with the underlying hypothesis that it would reduce left ventricular (LV) mass and EAT in obesity-related HFpEF. METHODS: A total of 175 patients with obesity-related HFpEF from the parent study of tirzepatide (2.5 mg subcutaneously weekly, increasing to a maximum of 15 mg weekly) or matching placebo underwent CMR at baseline, which consisted of multiplanar cine imaging. A total of 106 patients completed the CMR and had adequate image quality for analysis of LV and left atrial structure and function and paracardiac (epicardial plus pericardial) adipose tissue at both baseline and 52 weeks. The prespecified primary endpoint of this substudy was between-group changes in LV mass. RESULTS: LV mass decreased by 11 g (95% CI: -19 to -4 g) in the treated group (n = 50) when corrected for placebo (n = 56) (P = 0.004). Paracardiac adipose tissue decreased in the treated group by 45 mL (95% CI: -69 to -22 mL) when corrected for placebo (P < 0.001). The change in LV mass in the treated group correlated with changes in body weight (P < 0.02) and tended to correlate with changes in waist circumference and blood pressure (P = 0.06 for both). The LV mass change also correlated with changes in LV end-diastolic volume and left atrial end-diastolic and end-systolic volumes (P < 0.03 for all). CONCLUSIONS: The CMR substudy of the SUMMIT trial demonstrated that tirzepatide therapy in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared with placebo, and the change in LV mass paralleled weight loss. These physiologic changes may contribute to the reduction in heart failure events seen in the main SUMMIT trial. (A Study of Tirzepatide [LY3298176] in Participants With Heart Failure With Preserved Ejection Fraction [HFpEF] and Obesity: The SUMMIT Trial; NCT04847557).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
九司发布了新的文献求助30
刚刚
杨帅完成签到,获得积分10
刚刚
万能图书馆的应助被辉煌采纳,获得10
1秒前
1秒前
YXH发布了新的文献求助10
1秒前
cxr完成签到,获得积分10
1秒前
niuniu顺利毕业完成签到 ,获得积分10
2秒前
2秒前
2秒前
丫头发布了新的文献求助10
3秒前
阿澜完成签到,获得积分10
4秒前
mmm发布了新的文献求助10
5秒前
烟花的应助被开放的水壶采纳,获得10
5秒前
randi完成签到 ,获得积分20
5秒前
cxr发布了新的文献求助10
5秒前
科研通AI6.3的应助被翁宇轩采纳,获得10
5秒前
共享精神的应助被Zhang采纳,获得10
6秒前
7秒前
8秒前
8秒前
小羊完成签到,获得积分10
9秒前
9秒前
9秒前
丫头完成签到,获得积分10
10秒前
Even完成签到,获得积分10
10秒前
10秒前
10秒前
香蕉觅云的应助被孟翔采纳,获得10
11秒前
11秒前
黄毛虎发布了新的文献求助10
12秒前
我是老大的应助被牛哞采纳,获得10
13秒前
YXH发布了新的文献求助10
13秒前
yang发布了新的文献求助10
13秒前
yyyy发布了新的文献求助10
13秒前
Voyager发布了新的文献求助10
14秒前
zf2023完成签到,获得积分10
14秒前
豆豆豆发布了新的文献求助10
14秒前
吴允儿发布了新的文献求助10
14秒前
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187533
求助须知:如何正确求助?哪些是违规求助? 9575604
关于积分的说明 21842148
捐赠科研通 7785275
什么是DOI,文献DOI怎么找? 3434996
关于科研通互助平台的介绍 2559428
邀请新用户注册赠送积分活动 2481898